Solvay Raises Bid for Innogenetics; Gen-Probe Folds | GenomeWeb
NEW YORK (GenomeWeb News) - Solvay Pharmaceuticals today increased its bid to acquire Belgian molecular diagnostics firm Innogenetics to €6.50 per share from an initial offer that it made in April of €5.75 per share.
 
Gen-Probe, which made a counteroffer of €6.10 per share in early June, said today that it does not intend to increase its offer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.